The Antioxidant Megadose Myth: Why More Vitamin C and E Is Not Better

6 min read ·
Bottom Line

Megadose antioxidant supplementation does not prevent cardiovascular disease, cancer, or all-cause mortality; in several large trials it actively produces harm. Reactive oxygen species are not the villain the 1980s marketing assumed. Correct documented deficiencies, follow disease-specific formulations like AREDS2 where the trial evidence supports them, and otherwise get antioxidants from the foods that contain them rather than from megadose capsules.

The antioxidant supplement category was built on a simple chain of logic: free radicals cause oxidative damage, oxidative damage contributes to disease, so blocking free radicals with megadose antioxidants should prevent disease. That argument dominated supplement marketing from the 1980s through the early 2000s, and it was attractive enough that public-health agencies funded a series of very large randomized trials to test it. Those trials returned a strikingly consistent answer: high-dose antioxidant supplementation either does nothing measurable for the diseases it was meant to prevent, or it causes net harm, depending on the population studied. Decades later the megadose pitch survives in marketing while the trial evidence points firmly the other way.

What the large cardiovascular and cancer trials showed

The Women's Health Study randomized 39,876 healthy women to 600 IU of natural-source vitamin E on alternate days or placebo and followed them for an average of 10.1 years. There was no benefit for major cardiovascular events (relative risk 0.93; 95% CI 0.82–1.05) and none for total cancer (RR 1.01).1 The Physicians' Health Study II, a factorial trial in 14,641 male physicians, tested 400 IU of vitamin E every other day and 500 mg of vitamin C daily over a mean of 8 years. Neither vitamin reduced major cardiovascular events; vitamin E was actually associated with a higher risk of hemorrhagic stroke (HR 1.74).2

The cancer-prevention trials are more pointed. SELECT (the Selenium and Vitamin E Cancer Prevention Trial) randomized 35,533 men; with extended follow-up, vitamin E 400 IU daily was associated with a statistically significant 17% increase in prostate-cancer risk (HR 1.17; 99% CI 1.004–1.36).3 Two large beta-carotene trials were stopped early for harm: the Finnish ATBC study found 18% more lung cancers among smokers given beta-carotene,4 and the U.S. CARET trial found a 28% higher lung-cancer rate (and higher all-cause mortality) in smokers and asbestos-exposed workers given beta-carotene plus vitamin A.5

Pooling the field confirms the pattern. A 2007 meta-analysis of 68 randomized trials in 232,606 participants found no overall mortality benefit, and among the low-bias trials, beta-carotene, vitamin A, and vitamin E each significantly increased all-cause mortality; vitamin C and selenium showed no significant effect.6 The 2012 Cochrane update (78 trials, 296,707 participants) reached the same conclusion: beta-carotene and vitamin E increased mortality, and higher doses of vitamin A may as well.7

Why the underlying logic was wrong

Two assumptions broke down. First, reactive oxygen species are not purely destructive. They act as signaling molecules in vascular tone, insulin sensing, training adaptation, and the cell's own stress-response and antioxidant-defense systems. Blanket suppression interferes with that signaling. A controlled human trial illustrates this directly: when previously untrained and trained men supplemented vitamin C (1,000 mg/day) plus vitamin E (400 IU/day) during a four-week exercise program, the antioxidants abolished the exercise-induced improvement in insulin sensitivity and blocked the rise in the cell's endogenous antioxidant enzymes — benefits that appeared only in the no-supplement group.8 In other words, the megadose was not inert; it cancelled a health effect of exercise.

Second, the epidemiology that inspired the hypothesis tracked foods, not isolated vitamins. People who eat more fruits and vegetables have lower disease rates, but extracting the antioxidant vitamins from that food matrix and delivering them in pharmacologic doses does not reproduce the association. This is one of the most reproducible disappointments in nutrition science, and it points to the whole package — fiber, polyphenols, potassium, and the displacement of less healthy foods — doing more work than any single nutrient pulled out and concentrated into a capsule.

Where antioxidant supplementation still makes sense

The null and harm findings are about megadosing in well-nourished people for primary prevention. They do not abolish legitimate uses. Correcting a documented deficiency is still valid medicine: vitamin C for scurvy, vitamin E in fat-malabsorption syndromes or abetalipoproteinemia, selenium in regions where Keshan disease is endemic. And targeted, disease-specific formulations can work where generic megadosing fails. The AREDS2 trial tested an eye-specific combination (vitamin C, vitamin E, zinc, copper, plus lutein and zeaxanthin) in people at high risk of advanced age-related macular degeneration; notably, it replaced beta-carotene with lutein/zeaxanthin precisely because beta-carotene raised lung-cancer risk in former smokers.9 That is a specific intervention for a specific eye disease — not evidence for taking high-dose antioxidants to prevent heart disease or cancer in the general population.

For everyone else, the practical reading is straightforward. Vitamin C at physiological intakes (the 90 mg/day RDA, or the few hundred milligrams obtained from a produce-rich diet) is safe and sufficient; the 1,000–3,000 mg megadose tradition has no outcome evidence behind it and, in a large prospective cohort, supplemental vitamin C of 1,000 mg/day or more was associated with a 43% higher risk of kidney stones in men.10 The most defensible source of antioxidants remains the foods that contain them.

Related supplements

Sources

  1. Lee IM, Cook NR, Gaziano JM, et al. "Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial." JAMA, 2005;294(1):56-65. PMID 15998891.
  2. Sesso HD, Buring JE, Christen WG, et al. "Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial." JAMA, 2008;300(18):2123-33. PMID 18997197.
  3. Klein EA, Thompson IM, Tangen CM, et al. "Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)." JAMA, 2011;306(14):1549-56. PMID 21990298.
  4. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. "The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers." N Engl J Med, 1994;330(15):1029-35. PMID 8127329.
  5. Omenn GS, Goodman GE, Thornquist MD, et al. "Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease." N Engl J Med, 1996;334(18):1150-5. PMID 8602180.
  6. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. "Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis." JAMA, 2007;297(8):842-57. PMID 17327526.
  7. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. "Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases." Cochrane Database Syst Rev, 2012;(3):CD007176. PMID 22419320.
  8. Ristow M, Zarse K, Oberbach A, et al. "Antioxidants prevent health-promoting effects of physical exercise in humans." Proc Natl Acad Sci U S A, 2009;106(21):8665-70. PMID 19433800.
  9. Age-Related Eye Disease Study 2 (AREDS2) Research Group. "Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the AREDS2 randomized clinical trial." JAMA, 2013;309(19):2005-15. PMID 23644932.
  10. Ferraro PM, Curhan GC, Gambaro G, Taylor EN. "Total, dietary, and supplemental vitamin C intake and risk of incident kidney stones." Am J Kidney Dis, 2016;67(3):400-7. PMID 26463139.